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have implications for the spectrum of activity of any new inhibitors against bacterial species, as well as
the potential for development of drug resistance. In this review we assess similarities and differences in
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Architecture and Conservation of the Bacterial DNA Replication
Machinery, an Underexploited Drug Target
Andrew Robinson, Rebecca J. Causer and Nicholas E. Dixon*
School of Chemistry, University of Wollongong, Australia
Abstract: New antibiotics with novel modes of action are required to combat the growing threat posed by multi-drug
resistant bacteria. Over the last decade, genome sequencing and other high-throughput techniques have provided
tremendous insight into the molecular processes underlying cellular functions in a wide range of bacterial species. We can
now use these data to assess the degree of conservation of certain aspects of bacterial physiology, to help choose the best
cellular targets for development of new broad-spectrum antibacterials.
DNA replication is a conserved and essential process, and the large number of proteins that interact to replicate DNA in
bacteria are distinct from those in eukaryotes and archaea; yet none of the antibiotics in current clinical use acts directly
on the replication machinery. Bacterial DNA synthesis thus appears to be an underexploited drug target. However, before
this system can be targeted for drug design, it is important to understand which parts are conserved and which are not, as
this will have implications for the spectrum of activity of any new inhibitors against bacterial species, as well as the
potential for development of drug resistance. In this review we assess similarities and differences in replication
components and mechanisms across the bacteria, highlight current progress towards the discovery of novel replication
inhibitors, and suggest those aspects of the replication machinery that have the greatest potential as drug targets.

Keywords: DnaB, DnaC, DnaE, DNA polymerase IIIC, DnaG primase, helicase.
INTRODUCTION
The overuse of antibiotics during the past 60 years has
exerted strong selective pressure on pathogenic bacteria, driving many to develop effective mechanisms of drug resistance [1]. Among the most notorious examples are methicillin-resistant strains of Staphylococcus aureus (MRSA) and
vancomycin-resistant Enterococcus spp. (VRE), both Grampositives. An equal or perhaps greater threat, however,
comes from Gram-negative bacteria like Acinetobacter and
Pseudomonas spp., some strains of which are multi- or even
pan-drug resistant [2-4]. Resistant bacteria have developed
diverse strategies to evade antibiotic therapy and most
worryingly, appear to be developing resistance against an
ever-widening spectrum of antibiotic compounds [5]. There
is thus an urgent need for the development of new antibiotics
with entirely new modes of action to treat infections caused
by these highly resistant bacteria [1, 2, 6-8]. Unfortunately,
the development of novel antimicrobial compounds has all
but ceased in recent years, in part because existing antibiotics were so effective prior to the widespread dissemination
of drug resistant strains [2, 9]. Efforts to develop entirely
novel antibiotics have been hampered by the inherent difficulty of discovering appropriate cellular targets and functional lead compounds. Most antibiotics developed in recent
years have been simple modifications of older compounds,
aimed primarily at circumventing problems with resistance
[10].
The past decade has seen an explosion of data that
greatly enhance our knowledge of bacterial physiology [11*Address correspondence to this author at the School of Chemistry,
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17]. High-throughput genome sequencing initiatives have
generated more than 1000 complete bacterial genomes [18].
Many hundreds more are near completion. High-throughput
gene knockout studies have been used to determine the
essentiality of each individual gene in 14 different bacterial
species [14]. For well-studied model organisms, such as
Escherichia coli, large-scale attempts are being made to map
the entire cellular protein-protein interaction network [19].
Structural genomics initiatives have now determined threedimensional structures for many hundreds of bacterial
proteins [15]. In addition to these high-throughput studies,
researchers using more traditional approaches have made
many exciting discoveries in recent years. A highlight is the
use of fluorescence microscopy to study the actions of
individual proteins inside living bacterial cells, which has
added clarity to support decades of in vitro studies [20].
Crucially, the data derived from genome sequencing and
other high-throughput studies now allow us to extrapolate
much of the information derived from traditional work with
model organisms to other bacteria, including species that act
as human pathogens [21].
Are there new opportunities for the discovery of novel
antibiotic compounds buried within all these new data? Now
is an ideal time to collate this information and use it to assess
which among cellular processes might serve as useful targets
for drug discovery studies. In general, the biological targets
of antibiotics are: (i) essential for growth and propagation of
bacterial cells, (ii) conserved across a wide range of human
pathogens, and (iii) not present, or distinct from corresponding processes, in humans. Promisingly, there remain some
cellular systems in bacteria that satisfy these criteria, yet are
not the targets of any current antibiotics. These systems
might therefore include new targets for the rational design or
discovery of novel antibiotic compounds.

© 2012 Bentham Science Publishers

Bacterial DNA Replication as a Drug Target

The replication of chromosomal DNA is one such process. It is one of the most fundamental processes carried out
by bacteria, yet currently only one functional class of antibiotics (the DNA gyrase inhibitors) targets DNA replication,
and even then the mode of action is indirect [22]. The
mechanisms underlying bacterial DNA replication are now
well understood, particularly in E. coli [23-25]. DNA replication is carried out by a highly dynamic complex called the
replisome, comprised of at least 13 different proteins (Table
1). Complete replisome complexes from E. coli and Bacillus
subtilis have been reconstituted from individually purified
components and are fully functional in vitro [26, 27].
Minimal replicases have been assembled for other bacteria,
namely the Gram-positive pathogens S. aureus [28] and
Streptococcus pyogenes [29], the Gram-negative pathogen
Pseudomonas aeruginosa [30] and the hyperthermophile
Aquifex aeolicus [31]. Three-dimensional structures are now
available for nearly all of the individual protein modules and
even for some of the replisomal sub-complexes. The majority of protein-protein interactions have been mapped and are
being studied in increasingly finer detail [32]. With an
abundance of genome sequence data available, we can now
extrapolate our understanding of E. coli DNA replication to
other organisms [21].
Could new antibiotics be designed that target conserved
aspects of the DNA replication machinery? If so, will it be
possible to avoid the development of resistance encountered
so often in the past? In this review we summarize current
understanding of bacterial DNA replication, use genome
sequence data to map the conservation of replication components across the bacteria, summarize recent efforts to
develop DNA replication inhibitors and identify unexploited
components that are most likely to be useful as targets for
drug discovery and rational drug design.
BACTERIAL DNA REPLICATION
Although (often) functionally equivalent, the proteins
that replicate chromosomal DNA in bacteria (Table 1) are
distinct in sequence and structure from those in eukaryotes
and archaea. Despite their enormous genetic diversity, all
bacteria appear to share essentially the same mechanisms of
chromosomal replication and most of the replication proteins
are sufficiently conserved to be readily identified in translated genome sequences. Most bacteria contain a single circular chromosome, within which replication is initiated at a
single site, the origin of replication, oriC [33]. The two
strands of the template DNA are separated at the origin,
yielding two fork structures. Replicative DNA polymerases
(replicases) and accessory proteins are assembled onto each
of these forks, and synthesize new DNA bidirectionally
around the circular chromosome (Fig. 1A) until the two
replication forks meet in the terminus region (Ter), located
approximately opposite the origin. This eventually yields
two copies of the bacterial chromosome, each containing one
strand from the parental chromosome and one nascent
strand.
The best-studied bacterial replication system is that of E.
coli whose mechanism, for the most part, serves as a model
for all bacteria. In E. coli, oriC is recognized first by the
replication initiator protein DnaA, which exists in forms that
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contain tightly bound ATP or ADP. The origin contains a
series of five 9-bp sequence repeats known as DnaA (or R)
boxes, to which DnaA-ATP and DnaA-ADP bind, as well as
three additional sites (I boxes) that are specific for the ATPbound form [34, 35]. DnaA appears to remain associated
with boxes R1, R2 and R4 for most of the cell cycle. At the
onset of a round of DNA replication, binding of ATP-bound
DnaA molecules to the remaining sites (R3, I1, I2 and I3)
leads to separation of the two template DNA strands at a
nearby AT-rich region. Four separate systems regulate this
process, ensuring that replication is initiated only once during each cell cycle [34]. Following strand separation, one
ring-shaped hexamer of the replicative helicase DnaB
(DnaB6) is loaded onto each of the DNA strands in the same
orientation and each proceeds to unwind the parental DNA
duplex, creating replication forks that move away from the
origin in opposite directions. The replicase, DNA polymerase III holoenzyme (Pol III HE), associates with the
forks and synthesizes both new DNA strands, leaving two
completed duplex structures in its wake. Like most DNA
polymerases, Pol III cannot begin DNA synthesis on a
single-stranded DNA template; it can only extend preexisting DNA or RNA primers. It is the DnaG primase that
first associates with DnaB at the replication fork and
constructs short RNA primers, which are then extended by
Pol III to build each new DNA strand.
Following decades of contention, the stoichiometry of
individual components within active replisomes has recently
been measured in living E. coli cells [36]. While DnaG
primase was not quantified in this study, existing structural
and biochemical evidence indicate that three molecules are
likely to be present at each fork [37-39]. Each replisome is
comprised of two main sub-complexes: the primosome
([DnaB6][DnaG]3), and Pol III HE ([]3[3’()][ 2]3)
(Fig 1B). The Pol III HE in turn contains three different
subcomplexes: a single clamp loader complex (3’)
tethers three core polymerases (), each of which when
actively synthesizing DNA is associated with a dimeric sliding clamp. Three 2 dimers are present at each replication
fork [36]; the third could be associated with either the clamp
loader or with the third  core. Each Pol III HE thus
contains three polymerase cores that are tethered together
through the clamp loader complex, and to their DNA substrates by -sliding clamps. Each polymerase  subunit is
accompanied by a proofreading  subunit, an exonuclease
that removes errantly incorporated nucleotides at the 3’ end
of the newly synthesized strand. DNA synthesis by Pol III
core is carried out only in the 5’3’ direction; thus synthesis
of one nascent strand (the leading strand) is continuous while
synthesis of the other strand (the lagging strand) is discontinuous. Synthesis on the lagging strand occurs in four
stages. Firstly DnaG primase associates with the DnaB
helicase (which translocates on the lagging strand), recognizes a trinucleotide recognition sequence and produces an
RNA primer (of up to 14 nt). This happens about once every
1000 nt during lagging strand synthesis. A -sliding clamp is
loaded at the newly primed site by the clamp loader
complex, onto which a Pol III core then associates. The Pol
III core synthesizes new DNA until it reaches the preceding
primer, producing an ~1 kb Okazaki fragment. The Pol III
core is then transferred onto a subsequent (upstream) -
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Table 1. Bacterial DNA Replication Proteins

Protein

Function

Phylogenetic
distribution

Essentiality*

Enzymatic
activity†

Interaction partners

Structures‡ (organism)*

References

Initiation complex
DnaA

initiator

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Mt, Pa,
Sa

ATPase

Hda

initiation
suppressor

/ / proteobacteria

Ec, Pa

ATPase

YabA

initiation
suppressor

firmicutes

DnaB

helicase coloader

DnaC

DnaB, Hda, DiaA, Dps, 2HCB (Aa), 1L8Q (Aa), 2E0G
HU, DNA
(Ec), 2Z4R (Tm)

[161, 170-176]

, DnaA

3BOS (Sh)

[162, 177]

D

, DnaA

–

[178]

firmicutes,
tenericutes

Bs, Sa

DnaC (helicase), DnaD,
DnaI

–

[55, 179]

helicase
loader

enterobacteria,
Aquificae

Ec, St

DnaB (helicase), DNA

3ECC (Aa)

[49, 53, 54]

DnaD

DNA
remodelling

firmicutes

Bs, Sa, Sn

DnaB, DnaI

2V79 (Bs)

[55, 63, 180]

DnaI

helicase
loader

firmicutes

Bs, Sa, Sn

ATPase

DnaC (helicase), DnaB,
DnaD, DNA

2K7R (Bs), 2W58 (Gk)

[58, 181]

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Mt, Pa,
Sa, Sn

ATPase

DnaA, DnaC/DnaI,
DnaG, , Rep, DNA

2Q6T (Ta), 2VYE (Gk), 2R6A
(Gs), 1B79 (Ec), 1JWE (Ec),
2R5U (Mt)

[37, 53, 54, 63,
132, 139, 182186]

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Mt, Pa,
Sa, Sn

RNA primase

DnaB, SSB, DNA

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Mt, Pa, DNA polymerase
Sa, Sn

ATPase

Primosome
DnaB/DnaC DNA helicase

DnaG

DNA primase

1D0Q (Gs), 1DDE (Ec), 1EQN
[37, 39, 50, 54,
(Ec), 3B39 (Ec), 2R6A (Gs),
78, 137, 139, 140,
1Z8S (Gs), 2HAJ (Ec), 1T3W
187-189]
(Ec), 2AU3 (Aa)

DNA Pol III core
 subunit,
DnaE

polymerase
activity
 subunit,

/ / Ab, Ec, Fn, Hi, Pa
proteobacteria

exonuclease

, ,  , DNA

2HNH (Ec), 2HPI (Ta), 3E0D
(Ta)

[26, 164, 190194]

, , DNA

1J53 (Ec), 2IDO (Ec)

[192, 195-197]



2AXD (Ec), 2AE9 (Ec)

[198-200]

DnaQ

proofreading
activity

HolE

 subunit

enterobacteria

D

PolC

polymerase
activity

firmicutes,
tenericutes

Bs, Mg, Mp, Sa

DNA
polymerase/
exonuclease

, , DNA

3F2B (Gk), 2P1J (Tm)

[27, 28, 65, 75,
163, 190]

ATPase

, , ’, , , DnaB

2AYA (Ec), 3GLI (Ec), 1NJ5
(Ec), 1XXH (Ec)

[76, 201-204]

, ’, ,

3GLI (Ec), 1XXH (Ec), 1JQL
(Ec)

[76, 203, 205]

, ,

3GLI (Ec), 1XXH (Ec)

[76, 203]

DNA Pol III clamp loader
complex
DnaX

 and
subunits

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Mt, Pa,
Sa, Sn

HolA

 subunit

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mp, Pa

HolB

’ subunit

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Pa, Sa, Sn

HolC

 subunit

/ / proteobacteria

Hi

, SSB

1EM8 (Ec)

[78, 83, 206]

HolD

 subunit

-proteobacteria

D

, /

1EM8 (Ec)

[76, 84, 206]

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Pa, Sa

ATPase

Other replication proteins

DnaN

sliding
clamp

, , Hda, UmuC,
[26, 45, 172, 191,
UmuD, DinB1, MutS, 2POL (Ec), 1JQL (Ec), 2AVT
192, 205, 207(Sp)
MutL, DNA ligase, PolA,
212]
PolB, DNA
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(Table 1) Contd…..
Phylogenetic
distribution

Essentiality*

SSB

ssDNA
binding

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Pa, Sa, Sn

PolA

DNA
polymerase I

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Mt, Sa

DNA
polymerase/
exonuclease

, DNA

1DPI (Ec), 1KLN (Ec), 1KFS
(Ec), 3BDP (Gs), 3KTQ (Ta)

[190, 210, 226230]

LigA

DNA ligase

all bacteria

Ab, Bs, Ec, Fn, Hi,
Mg, Mp, Mt, Pa,
Sa, Sn

DNA ligase

, DNA

2OWO (Ec), 1DGS (Tf), 1B04
(Gs), 1TA8 (Ef), 3JSL (Sa),
1ZAU (Mt)

[210, 231-235]

DNA
gyrase

DNA
supercoiling

all bacteria

Ab, Bs, Ec, Fn, Hi,
topoisomerase
Mg, Mp, Mt, Pa,
ATPase
Sa, Sn

GyrI, CcdB, DNA

2WL2 (Ec), 2XCQ (Sa), 2XCS
(Sa), 2XCT (Sa)

[103, 106]

Tus

terminator

enterobacteria

D

DNA

2EWJ (Ec)

[43]

RTP

terminator

some bacillales

D

DNA

2EFW (Bs), 1BM9 (Bs),
1F4K (Bs)

[44, 236, 237]

Protein

Function

Enzymatic
activity†

Interaction partners

Structures‡ (organism)*

References

DnaG, , RecQ, TopB,
1EQQ (Ec), 1Z9F (Tm), 2VW9
[46, 78, 79, 81UmuC, RecJ, PriA,
(Hp), 1SE8 (Dr), 1UE1 (Mt),
83, 167, 213-225]
RecO, exonuclease I,
2FXQ (Ta)
GroEL, DNA

* Organism designations: Aa, Aquifex aeolicus; Ab, Acinetobacter baylyi; Bs, Bacillus subtilis; Dr, Deinococcus radiodurans; Ec, Escherichia coli; Ef, Enterococcus faecalis; Fn,
Francisella novicida; Gk, Geobacillus kaustophilus; Gs, Geobacillus stearothermophilus; Hi, Haemophilus influenzae; Hp, Helicobacter pylori; Mt, Mycobacterium tuberculosis; Mg,
Mycoplasma genitalium; Mp, Mycoplasma pulmonis; Pa, Pseudomonas aeruginosa; Sa, Staphylococcus aureus; Sm, Shewanella amazonensis; Sn, Streptococcus pneumoniae; Sp,
Streptococcus pyogenes; St, Salmonella typhimurium; Ta, Thermus aquaticus; Tf, Thermus filiformis; Tm, Thermatoga maritima; Vc, Vibrio cholerae; D, dispensable; gene not found
to be essential in any organism.
†
, no activity or no structure available
‡
Codes shown are Protein Data Bank accession number

loaded primer to begin synthesizing a new fragment. The
RNA primers between fragments are removed by ribonuclease HI and/or DNA polymerase I and replaced with
DNA by the latter enzyme. Finally the DNA fragments are
joined by DNA ligase to create a continuous lagging DNA
strand. Throughout DNA synthesis, available template
strands are coated by tetramers of the single-stranded DNAbinding protein, SSB, which maintains contact with the
replisome through interactions with primase and the 
subunit of the clamp loader. Despite the complexity of this
process, DNA synthesis occurs with remarkable fidelity and
at an astonishing rate, close to 1000 nt per second [40]. The
bidirectionality of chromosome synthesis means that
replication of the 4.6 Mb E. coli chromosome is completed
in about 40 min. Coordinated leading and lagging strand
synthesis requires that the replisome be highly dynamic, with
components frequently being switched from one part of the
template to another. This is made possible through a
complex series of protein-protein interactions, some of
which are only transient, that coordinate the various
enzymatic modules within the replisome assembly.
Three-dimensional structures have now been determined
for practically all the functional modules within the bacterial
replisome, using proteins from E. coli and/or other organisms (Table 1). The network of protein-protein interactions
has been largely determined. Inclusive of initiation complexes, replisome components, SSB, DNA polymerase I and
DNA ligase, replication of the bacterial chromosome at the
very least requires nine distinct enzymatic activities and ten
different protein-protein contacts to be made [32]. These
numbers are even greater when essential, but non-universal,
components (e.g. helicase loaders) are included. Each of
these activities/interactions represents a potential target site

for interference by antibiotic compounds. Despite this, very
few inhibitors specific for bacterial DNA replication components are available and the replication machinery remains
an underexploited target for antibacterial chemotherapy. It is
important, however, to consider our knowledge of DNA
replication in the context of all bacteria, not just model
organisms, if we are to choose DNA replication proteins as
targets for drug discovery or rational drug design.
CONSERVATION
OF
DNA
COMPONENTS IN BACTERIA

REPLICATION

With the abundance of bacterial genome sequence data
now available, the sequence conservation and phylogenetic
distribution of DNA replication proteins is becoming clear
(Table 1). There is a basic replication module that is present
in all bacteria and probably arose early in evolutionary
history: the DnaA replication initiator, DnaB helicase (called
DnaC in firmicutes like Bacillus spp.), DnaG primase, Pol III
 (plus an additional, related PolC in some organisms), 2, 
(part of PolC when PolC is present), 3,  and ’, SSB, DNA
polymerase I and DNA ligase. This set of proteins constitutes all of the components necessary to carry out and
coordinate leading and lagging strand synthesis on a doublestranded DNA template [26, 27]. Other modules are restricted to particular phylogenetic groups and are likely
therefore to have evolved more recently, presumably helping
to regulate replication events. Some attributes, such as the
fusion of ribonuclease HI to the  subunit of Pol III core [21,
41], have a very restricted distribution (in this case to the
family Moraxellacae). Certain other properties, such as the
presence of replication termination systems in the
Enterobacteriacae (Tus-Ter [42, 43]) and firmicutes (RTP-
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B

fork progression

fork progression

leading strand

oriC

α
ε
α
DnaB helicase

ε

3’
5’

β
δ'
δ

τ
τ

RNA
primer

τ

Okazaki fragment

β α
ε

DnaG primase

DNA ligase

Pol III

3’
5’

β
Pol I

lagging strand
SSB

Ter

C

D

E
DnaA
Escherichia coli
Klebsiella pneumoniae
Salmonella enterica
Persephonella marina
Aquifex aeolicus
Hydrogenobacter thermophilus
Clostridium botulinum
Streptococcus pyogenes
Bacillus subtilis
Staphylococcus aureus

G

DnaC

DnaI

le
eading strand
leading

PolC

3’
5’

3’
5’

τ3δδ'
PolC

primase

DnaC

leading strand

PolC

helicase

F

0.2

DnaE

τ3δδ'
Okazaki
fragment

3’
5’

helicase

DnaE

primase

PolC

lagging strand

SSB

i. primer extension

Okazaki
fragment

3’
5’

lagging strand

SSB

ii. elongation

Fig. (1). Architecture and conservation of bacterial replisomes. (A) Bidirectional replication of a circular bacterial chromosome initiates
at oriC and terminates opposite. Green circles denote replisomes at replication forks. (B) Model for leading and lagging strand synthesis at a
replication fork in E. coli. (C) Overlaid ribbon diagrams of the AAA+ domains of DnaA (PDB: 2HCB, blue), DnaC (PDB: 3ECC, green),
DnaI (PDB: 2W58, pink) and Hda (PDB: 3BOS, cyan). The position of the ATP analog AMP-PCP (colored by atom type: C, yellow; N,
blue; O, red; P, orange) and a Mg2+ ion (gray sphere) within the DnaA structure is shown. (D) Overlaid ribbon diagrams of the AAA+-like
domains of the clamp loader subunits  (blue),  (magenta), and ’ (green). Coordinates were derived from PDB: 3GLI. The positions of
ADP (colored by atom type, as above for ATP), the phosphate transition state analog BeF3 (Be, magenta; F, cyan) and a Mg2+ ion (gray
sphere) within the  subunit are shown. (E) Phylogenetic tree based on the sequences of DnaC/DnaI helicase loader proteins. The tree was
constructed using the neighborhood-joining tree method in Geneious (Biomatters, Auckland, New Zealand), using the Jukes-Cantor genetic
distance model and employing the bootstrap method with 100,000 replicates. The sequence of E. coli DnaA was included as an outgroup.
Colored boxes indicate helicase loader families (enterobacteria DnaC-type, cyan; Aquificae DnaC-type, pink; firmicute DnaI-type, green).
(F) Ribbon diagrams showing filaments of Aquifex aeolicus DnaC (PDB: 3ECC) formed by P61 crystal packing [49]. (G) Model for
polymerase handover during lagging strand synthesis in Bacillus subtilis [27]. Panels (C), (D) and (F) were created using PyMOL [169].
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Ter [44]), are not essential for cell growth and are therefore
of limited interest with respect to drug discovery. Only those
components that are essential in those organisms that have
them are discussed further.
In general the sequences of DNA replication proteins are
moderately conserved among all bacteria. The genetically
distant E. coli and B. subtilis, for example, share 11–49%
sequence identity with respect to the proteins comprising the
basic replication module. Overall the sequences of these
proteins are less conserved than those of proteins involved in
other informational processes such as RNA transcription and
protein translation, but more conserved than proteins that
function in metabolic pathways and other non-informational
processes such as cell division [21]. Within the replication
proteins, sequence motifs that encompass enzymatic sites are
far more conserved than regions that mediate protein-protein
interactions. Similarly, whole proteins that contain enzymatic active sites tend to be more conserved than those that
only mediate protein-protein interactions. Notable exceptions
to this are the highly conserved protein-protein interaction
systems present on the -sliding clamp and SSB [21, 45, 46].
Several DNA replication proteins are paralogs of each
other or share structurally related domains. Many belong to
the AAA+ family of ATPases, which harness the energy
liberated by ATP hydrolysis to perform mechanical functions [47]. Within particular replication sub-complexes the
AAA+ proteins are clearly related to each other. The initiator
protein DnaA, for example, is closely related to the Hda
initiation regulator and (when they are present) the helicase
loaders DnaC and DnaI (Fig. 1C) [48, 49]. Similarly, the , 
and ’ subunits of the clamp loader complex [47], while not
all enzymatically active as ATPases, share significant
sequence homology and have similar overall structures (Fig.
1D). These similarities suggest that the members of each
sub-complex often share a common ancestor; they presumeably arose through ancient gene duplication events, eventually diverging to take on distinctive roles in the replication
process.
Structural homology is also seen among individual
domains of some replication proteins. The N-terminal
domain of the replicative helicase and the C-terminal domain
of DNA primase, which interact to facilitate RNA primer
synthesis, share a common fold despite negligible sequence
similarity [39, 50, 51]. To date this fold has only been
observed in these two proteins. Interestingly, weak sequence
homology has recently been revealed for domains of two
other replication proteins; the DnaB and DnaD replication
initiator accessory proteins found in firmicutes (Table 1).
Using Hidden Markov Model-based homology searches,
Marston and colleagues were able to recognise two distinct
homologous domains, DDBH1 and DDBH2, within these
proteins [52]. DnaD has a DDBH1-DDBH2 domain structure
while DnaB includes two DDBH2 domains and is arranged
DDBH1-(DDBH2)2. Despite their extreme sequence divergence, these domains share common attributes within the
two proteins: the DDBH1 domains facilitate subunit tetramerization while the DDBH2 domains bind to DNA (doublestranded DNA for DnaD and the C-terminal domain of
DnaB; single-stranded DNA for the first DDBH2 domain of
DnaB) and consequently facilitate protein oligomerization.
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Loading of the Replicative Helicase at oriC
The process of loading the replicative helicase at the
origin has primarily been studied in two model organisms,
the Gram-negative enterobacterium E. coli and the Grampositive firmicute B. subtilis. In both, the helicase associates
with DnaA during loading. In E. coli, DnaA-dependent
recruitment of DnaB at oriC requires the helicase to be in a
complex ([DnaB6][DnaC]6) with its loader protein DnaC
[53]. DnaC suppresses the ATPase activity of DnaB and
remains bound throughout the loading process. Once loaded,
primase associates with the helicase, triggering the release of
DnaC to enable strand separation by the helicase to
commence [54]. Loading of the replicative helicase (called
DnaC) in B. subtilis follows a similar mechanism except that
the helicase loader is called DnaI and the two additional
proteins described above, DnaB and DnaD, are also required
[55]. Smits and colleagues have recently delineated the order
of protein associations at oriC that precede helicase loading
in this organism [55]. DnaA binds first to oriC. The DNA
remodeling protein DnaD is then recruited, either through
interaction with DnaA or through direct interaction with nonB-form DNA within the DnaA-coated oriC. Membraneassociated DnaB molecules are then recruited, probably
through direct interaction with DnaD. Finally, two DnaC
helicase-DnaI helicase loader complexes associate with the
origin, at which point the two helicase hexamers are loaded
onto the DNA. The E. coli DnaC and B. subtilis DnaI loader
proteins share significant sequence homology, suggesting
that this final step might be somewhat conserved between
the two organisms. Interestingly however, relatives of these
loader proteins can only be found in a few select groups of
organisms outside of the enterobacteria and firmicutes.
Members of the Aquificae, a small group of hyperthermophilic Gram-negative rods that includes the model
organism Aquifex aeolicus [56], maintain a helicase loader
known as DnaC that is a homolog of E. coli DnaC and B.
subtilis DnaI [49]. As with E. coli, no relatives of B. subtilis
DnaB or DnaD are present in these organisms. For this
reason, the Aquificae DnaC proteins have been considered
functionally equivalent to E. coli DnaC. Phylogenetic
sequence analysis demonstrates, however, that Aquificae
DnaC proteins are only distantly related to the other DnaC/I
helicase loaders (Fig. 1E). This suggests that Aquificae
DnaC proteins represent their own distinct family of helicase
loaders and that they might have unique characteristics
relative to members of the other two families.
Collectively, the DnaC/I-type helicase loaders are twodomain proteins, with helicase binding being mediated
through the N-terminal domain while ATPase activity and
DNA binding occurs within the C-terminal AAA+ domain.
Crystal structures of the C-terminal domains of A. aeolicus
DnaC [49] and Geobacillus kaustophilus DnaI [57] reveal
very similar overall structures (Fig. 1C). Sequence homology within this region suggests that the C-terminal domain
of E. coli DnaC is probably also similar to the equivalent A.
aeolicus and G. kaustophilus domains. The A. aeolicus
domain was seen to form helical filaments in the crystalline
state (Fig. 1F), reminiscent of filaments previously observed
for ATP-bound DnaA from E. coli [49]. This helical
arrangement is thought to represent a structure important for
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helicase loading in vivo [49]. The fact that the C-terminal
domains of helicase loaders are well conserved across the
three families suggests that E. coli DnaC and B. subtilis DnaI
probably also adopt helical arrangements during helicase
loading.
The solution structure of the N-terminal domain of B.
subtilis DnaI determined by NMR, which revealed a novel
zinc-binding fold, provides the only structural definition of a
helicase loader N-terminal domain [58]. The sequences of
the N-terminal domains are conserved within each of the
three helicase loader families; however these domains in E.
coli and A. aeolicus DnaCs are clearly unrelated to that of B.
subtilis DnaI. For both E. coli DnaC and B. subtilis DnaI, it
is this N-terminal domain that facilitates binding to the
helicase [53, 59]. Further work is required to determine if the
structural basis of the helicase-helicase loader interactions is
in any way conserved among the three helicase loader
families.
The fact that DnaC/I-type helicase loaders are not
conserved among all bacteria implies that organisms outside
of the enterobacteria, firmicutes and Aquificae must either
not require specialized helicase loader proteins or utilise
proteins that are unrelated to DnaC/I for this function [21].
In support of the former scenario, Soni and colleagues have
shown that the helicase from Helicobacter pylori, an
organism that lacks an identifiable helicase loader, can be
used to complement a temperature-sensitive dnaC mutant of
E. coli [60]. This implies that the H. pylori helicase can be
loaded onto the E. coli oriC using the E. coli machinery in
the absence of a functional DnaC. One possibility is that
DnaA could itself be sufficient for loading of the replicative
helicase at oriC in organisms that lack helicase loaders.
Indeed the helicases from two such organisms, Pseudomonas
putida and P. aeruginosa can be loaded onto oriV of the
RK2 plasmid in vitro using only DnaA [61]. In the same
system, the E. coli helicase required DnaC to be present for
loading onto oriV [61]. Another possibility is that organisms
without DnaC/I might utilise replication restart complexes
analogous to the PriA/PriB/DnaT system found in E. coli
[62] to load the helicase at both origin and non-origin
sequences. In fact in B. subtilis, the DnaB and DnaD proteins
are required for loading the helicase both during initiation of
DNA replication and for replication restart [63]. Interestingly, homologs of B. subtilis DnaB are maintained within
members of the tenericutes, which lack homologs of DnaD
and DnaI (Table 1). In this case it is tempting to speculate
that DnaB might assist other, as yet unidentified, helicase
loaders in loading the helicase at oriC.
While helicase loaders are not found in all bacteria, they
form an essential part of the DNA replication machinery in
those organisms that have them (Table 1). Importantly, this
includes several important human pathogens, such as E. coli,
Salmonella typhimurium, Bacillus anthracis, Listeria
monocytogenes, Clostridium botulinum, Staphylococcus
aureus and Streptococcus pyogenes. For these organisms,
helicase loaders might represent useful antibacterial drug
targets. One could imagine, however, that relatively simple
modifications to other helicase loading pathways (such as
those involved in replication restart) might allow bacteria to
survive should their DnaC/DnaI pathways be inhibited.
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Ultimately this may limit the usefulness of helicase loader
inhibitors as antibiotics.
DnaE1 versus PolC + DnaE3 Mechanisms
The majority of bacterial genomes sequenced to date
contain a single type of replicative polymerase, the Pol III 
subunit, known under the polymerase classification scheme
developed by Zhao and colleagues as DnaE1 [64]. It has
long been known, however, that the Gram-positive B.
subtilis uses two related, but distinct, replicase types known
as PolC and DnaE3 [27, 64]. DnaE3 is homologous to
DnaE1 and has a similar domain organization, while PolC is
more distantly related to DnaE1, contains an additional related proofreading domain, and has a dissimilar arrangement of functional domains [64]. Both PolC and DnaE3 are
required for DNA replication in B. subtilis [65]. Based on the
observation that DnaE3 deprivation immediately halts lagging strand synthesis, while allowing leading strand
synthesis to continue, it was originally hypothesized that
PolC and DnaE3, respectively, constitute separate leading
and lagging strand replicases [65], akin to the eukaryotic
polymerases Pol  and Pol  [66]. Recently however,
reconstitution of a functional B. subtilis replisome in vitro
has shown that this is not the case [27].
After identifying 13 proteins likely to comprise the
replisome of B. subtilis (polymerases PolC and DnaE3, SSB,
PriA, DnaG primase, DnaC helicase, DnaB, DnaD, and DnaI
helicase loaders, the clamp, and the clamp loader subunits
, , and ’), Sanders and colleagues were able to purify each
of these components and use them to carry out coordinated
leading and lagging strand synthesis on a synthetic
minicircle DNA template [27]. All 13 proteins were found to
be required for lagging strand synthesis while DnaE3 and
primase could be omitted for leading strand synthesis. It was
found that both PolC and DnaE3 could extend DNA primers,
but only DnaE3 could extend RNA primers like those laid
down by primase. Inclusion of both PolC and DnaE3 had a
strong synergistic effect on the rate of lagging strand
synthesis. These observations are consistent with a model in
which DnaE3 does not act as a dedicated lagging-strand
polymerase, but rather acts to extend the RNA primers laid
down by primase with a short stretch of DNA so that PolC
can continue DNA synthesis (Fig 1G). The role of DnaE3 is
thus analogous to that of the eukaryotic Pol , which extends
RNA primers with DNA before handing them over to the
lagging strand Pol  [27]. As PolC/DnaE3 are present in all
firmicutes and tenericutes, this model probably applies to all
organisms within these groups.
Clamp Loader Subunits of DNA Polymerase III
At the heart of the Pol III holoenzyme (minimally
[]3[3’][ 2]2) is the heteropentameric clamp loader
complex (3’). As its name suggests, this complex functions to load -sliding clamps onto DNA primer-templates,
bestowing leading- and lagging-strand processivity on the
replicase [67]. Each of the three  subunits of the clamp
loader also binds to the  subunit of a polymerase core, thus
tethering three polymerases together to coordinate synthesis
of the two strands [36]. In E. coli the dnaX gene encoding
the  subunit includes sequence elements that induce a
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ribosomal frameshift with approximately 50% efficiency
[68-72]. This frameshift gives rise to a truncated form of ,
known as , comprising the N-terminal three domains out of
five in the full-length  protein; can replace  to form
complexes that maintain clamp loading activity, but since it
is the C-terminus of  that contacts , cannot multimerize 
subunits to form a functional replicase. It has long been
thought that the clamp loader complex in E. coli contains
two  subunits and one , thus yielding a Pol III HE with two
polymerase cores ([]2[2 ’][ 2]2). Recently however,
the Leake and Sherratt groups have quantified each of the
Pol III HE subunits at replication forks in living E. coli cells
[36], presenting strong evidence that in vivo, replicases
contain three  subunits and three  cores. The authors
instead propose that clamp loader complexes containing
subunits could function in other processes that require
loading of -sliding clamps, such as in DNA repair [36]. The
programmed ribosomal frameshift encoded within the E. coli
dnaX gene is also conserved in the related organism
Salmonella typhimurium [73]; in fact similar frameshift
sequences are found within dnaX genes among all the
enterobacteria. The dnaX gene of the hyperthermophilic
Gram-negative organism Thermus thermophilus also
produces both  and
products [74]. In this case
is
produced by transcriptional slippage rather than a ribosomal
frameshift. Most other bacteria, however, do not maintain
frameshift signatures within their dnaX genes and may not,
therefore, produce subunits. Indeed the dnaX genes from B.
subtilis, S. aureus, S. pyogenes, P. aeruginosa and A.
aeolicus produce only full-length  products when expressed
in recombinant E. coli systems [27-31, 75]. It appears likely
that all bacteria maintain three  subunits within clamp
loader complexes at replication forks and thus utilise trimeric
polymerases to replicate their chromosomes.
In addition to ,  and ’ subunits, the clamp loader
complexes of -proteobacteria include a heterodimeric subcomplex made up of the  and  subunits (Table 1). This is
tethered to the more universal clamp loader assembly (3’)
through an interaction between the N-terminus of  and
domain III from all three of the  subunits [76, 77]. The 
subunit interacts with the C-terminus of SSB, providing a
mechanism for the handover of primed template DNA from
primase to Pol III HE during lagging strand synthesis [7882]. Recently, the link between SSB and Pol III afforded by
the  heterodimer has been shown to be crucial for strand
displacement activity of Pol III HE [83]. It has also been
demonstrated that the interaction of  with  significantly
stimulates clamp-loading activity in E. coli and P.
aeruginosa [30, 76, 77, 84]. Interestingly, while only one 
heterodimer can associate with each clamp loader complex,
there are on average four  heterodimers at each replication
fork in live E. coli cells, compared with one 3’ complex
[36]. This suggests that additional  heterodimers associate
with SSB at replication forks, awaiting handover to Pol III
HE.
The gene encoding , holC, is dispensable in most
organisms (Table 1) [14]) and can be disrupted in E. coli,
although such disruptions show some growth defects [85].
The holD gene, which encodes  is dispensable in E. coli
[85] but essential in both Acinetobacter baylyi [86] and P.
aeruginosa [87]. The  proteins in these latter organisms are
much longer than their E. coli counterpart and might
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therefore carry additional functions that are essential for
survival [21, 84]. That the genes encoding  and/or  can be
disrupted in E. coli and other bacteria suggests that their role
in DNA replication is probably regulatory rather than being
part of some fundamental mechanism. Interestingly, genes
encoding  appear to be distributed across more of the
bacteria (, and -proteobacteria) than genes encoding 
( -proteobacteria only; see Table 1). The  proteins have
highly divergent sequences [21]; thus it is possible that the 
homologs in
and -proteobacteria have simply diverged
beyond the detection limit of sequence similarity searches,
including sensitive Hidden Markov Model-based methods
[88, 89]. If there is a genuine discrepancy in the phylogenetic
distribution of  and  subunits, however, this suggests that
 may have evolved to interact directly with  and/or have
extra functions outside of clamp loader complexes.
Gene Duplications
Genome sequencing has revealed that many bacteria
contain genes coding for multiple versions of certain replication proteins. Many of these proteins are potential drug
targets and are discussed in detail in the next section. The 
subunit of Pol III, which provides the major DNA polymerase activity of the replisome, exists in at least four
variants termed DnaE1, DnaE2, DnaE3 and PolC [64]. The
first three variants have a similar sequential arrangement of
PHP, polymerase and OB-fold domains within their primary
sequences, yet can be classified into three different groups
using sequence analysis. PolC proteins have regions homologous to the domains found in DnaE-type polymerases, as
well as an additional proofreading exonuclease domain. The
arrangement of domains is different however, appearing in
the primary sequence in the order OB-fold, PHP domain,
exonuclease and finally the polymerase domain. As discussed above, all bacteria outside of the firmicutes and
tenericutes have DnaE1, while organisms within these
groups have both PolC and DnaE3. In contrast, DnaE2 does
not conform to phylogenetic boundaries and can co-exist
with DnaE1 or PolC and DnaE3. The error-prone DnaE2
variant forms part of a LexA-regulated adaptive mutagenesis
cassette, which appears to have originated in the actinobacteria but has since disseminated throughout other bacterial
groups through lateral gene transfer [90]. DnaE2 variants are
found in the important human pathogens Mycobacterium
tuberculosis and P. aeruginosa and are likely to play a role
in the development of antibiotic resistance in these organisms [91, 92].
Other duplications of DNA replication proteins have
more mysterious functions. The genomes of many Bacillus
spp. contain a second copy of the dnaN gene, dnaN-2, coding for a -sliding clamp (DnaN-2) that shares approximately 40% sequence homology with its canonical-type sliding clamp (DnaN-1) [93]. In E. coli the -clamp is
known to bind to the  subunit of Pol III as well as a host of
DNA repair enzymes, thus playing a role in both replication
and repair [45]. In B. anthracis, deletion of dnaN-2 produces
a phenotype indistinguishable from wild-type, whereas
deletion of dnaN-1 results in a mutator phenotype [93]. This,
together with the fact that a dnaN-1/dnaN-2 double mutant
could not be produced, suggests that DnaN-1 functions in
both DNA replication and repair, while DnaN-2 can
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participate in replication but is deficient in one or more DNA
repair functions.
Duplications of genes encoding the  subunit of Pol III
(dnaQ), DNA primase (dnaG) and SSB (ssb) can also be
found within the genomes of a variety of diverse bacteria,
not conforming to any obvious phylogenetic boundaries.
While some attempts have been made to characterize the
products of these duplicated genes, their biological roles
remain unclear [94, 95]. Nevertheless, it is important to
consider the existence of these gene duplications if the
canonical versions of the proteins they encode are to be
considered as drug targets, in particular whether any functional redundancy may provide a selective advantage to their
hosts when challenged by antibiotics. On the other hand, if
two essential proteins with different functions are sufficiently similar to be targeted by the same drug, then this
would provide a substantial barrier to selection of resistant
mutants in either.
EXISTING INHIBITORS AND CURRENT SCREENING STRATEGIES
Of all the antibiotics in current clinical use, only two
classes inhibit the process of DNA replication. The quinolone and aminocoumarin drugs inhibit the action of DNA
gyrase, a type II toposiomerase that introduces negative
supercoils in DNA ahead of replication forks to enable
continued strand separation by the helicase during DNA
replication [96]. Given that the replication machinery
includes so many other proteins with functions essential for
bacterial viability, it is likely that at least some are useful
drug targets. The replisome is very much an under-explored
target for drug development, however, and few attempts to
discover specific inhibitors have been described. One of the
major challenges in discovering DNA replication inhibitors
has been the need for biochemical assays that can be used for
high-throughput screening. Important advances have been
made in this area recently and are likely to yield new inhibitors in the near future. This section describes inhibitors that
have been identified so far and the current strategies used for
discovering new antagonists of replication activity.
DNA Gyrase Inhibitors
Gyrase (a type IIA DNA topoisomerase) plays an
essential role in DNA replication, actively underwinding the
double-stranded template DNA ahead of the replication fork
to obviate effects of positive supercoiling induced by the
progressing replisome. It acts by cutting both DNA strands,
passing double-stranded DNA through the gap, then religating the original ends [97]. It is a heterotetrameric enzyme
comprised of two different subunits: GyrA, which binds
DNA and carries out strand cleavage/ligation, and GyrB,
which hydrolyses ATP to drive the supercoiling reaction.
Gyrase is the cellular target of several different classes of
bacteriocidal agents, including the highly-successful fluoroquinolone antibiotics, coumarins and cyclothialidines that
are currently undergoing drug development, as well as a
range of naturally-occurring bacterial toxins [22, 97]. Much
of the current research on gyrase inhibitors focuses on
modifying existing scaffolds to address issues with drug
resistance, toxic side effects and poor cellular penetration, as
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well as to broaden the range of bacterial species that compounds are active against [22, 97, 98]. Structure-aided design
and virtual screening techniques have proven somewhat
successful in delivering new classes of gyrase inhibitors,
some of which show broad-spectrum antibacterial activity
and reduced rates of resistance relative to exisiting drugs [99,
100]. Most recently, there has been exciting progress with
two novel classes of gyrase inhibitors that show great
promise for development into new antibiotics in the near
future.
The novel antibiotic simocyclinone D8 was originally
identified in extracts from the antibiotic-producing bacterium
Streptomyces antibioticus Tü 6040 [101]. This compound
has a chlorinated aminocoumarin group linked to an angucyclic polyketide moiety through a tetraene linker and a Dolivose sugar (Fig. 2A). The presence of the aminocoumarin
group suggested DNA gyrase to be the cellular target and
simocyclinone D8 was shown to potently inhibit the E. coli
enzyme in vitro [102]. Unlike the aminocoumarin antibiotics
however, simocyclinone D8 was found not to inhibit the
ATPase activity of the GyrB subunit, nor did it stimulate the
formation of unproductive cleavage complexes within the
GyrA subunit as seen with quinolone compounds, suggesting
an entirely novel mode of inhibition [102]. Edwards and
colleagues have recently determined the crystal structure of
simocyclinone D8 in complex with the N-terminal domain of
the GyrA subunit, revealing binding pockets for the aminocoumarin and polyketide moieties close to, but distinct from
a previously identified quinolone-binding site [103]. This
represents a significant step in the development of simocyclinones into clinically useful antibiotics, as structure-based
activity relationships can now be explored. In addition to this
binding site within the GyrA subunit, biochemical studies
have suggested the existence of a second low-affinity binding site within GyrB [104]. Further work is now required to
explore the possibility of cooperative binding at the GyrA
and GyrB sites. Interestingly, while simocyclinone D8 shows
poor activity against Gram-negative laboratory bacteria and
is thus being viewed as a potential treatment only for infections caused by Gram-positives, it has recently been found to
have potent activity against a number of Gram-negatives
isolated from clinical samples [105]. This observation is
likely to assist in identifying parameters that can be optimized to broaden the spectrum of activity of simocyclinones,
and adds to the promise of these compounds becoming
clinically useful antibiotics.
A very promising new antibiotic that acts on gyrase has
been recently described by GlaxoSmithKline researchers
[106]. GSK299423 (Fig. 2B) is a member of the novel bacterial topoisomerase inhibitors (NBTI) family of compounds,
which has also been explored by Novoxel [107] and Johnson
& Johnson [108, 109]. GSK299423 strongly inhibits the
activity of S. aureus and E. coli gyrase in vitro (IC50 = 14–
100 nM), making it more than 2000 times more potent than
the widely used drug ciprofloxacin (a fluoroquinolone)
[106]. GSK299423 shows potent antibacterial activity
against a range of Gram-positive and Gram-negative
pathogens (MIC = 0.016–8 μg/mL), including strains that are
resistant to fluoroquinolones. The crystal structure of the
gyrase-DNA-GSK299423 complex has been determined
using the S. aureus enzyme, revealing that the compound
binds between the active sites of the two GyrA subunits,
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Fig. (2). Chemical structures of new inhibitors of DNA gyrase. (A) Simocyclinone D8 [101-105]. (B) GSK299423 [106].

away from known binding sites for quinolone-type inhibitors
[106]. GSK299423 appears to inhibit the catalytic cycle of
gyrase by stabilizing a pre-cleavage enzyme-DNA complex,
an entirely novel mode of gyrase inhibition. Taken together,
the potency of GSK299423, its broad-spectrum activity and
its lack of cross-resistance with existing fluoroquinolones
suggest the NBTIs represent exciting candidates for
development into a much-needed new class of antibiotics
with a novel mode of action.
Inhibitors of DNA Polymerase Activity
DNA polymerases are the targets of several important
anti-viral and anti-cancer drugs, yet few inhibitors exist for
the equivalent bacterial enzymes [110]. To date, there are no
known inhibitors that are specific for DnaE1-type polymerases (e.g. the  subunit of E. coli Pol III). Two classes of
compounds are known to effectively inhibit the PolC-type
polymerases found in the firmicutes and tenericutes: 6anilinouracils (6-AUs) and quinazolin-2-ylamino-quinazolin4-ols (BisQuinols). Members of a third class of compounds,
the dichlorobenzylguanines, have been shown to inhibit the
activities of DnaE1-, DnaE3- and PolC-type polymerases,
although no analysis of their antimicrobial properties has
been published since their syntheses were described six years
ago [111].
The 6-anilinouracils are the oldest and most developed
class of DNA polymerase inhibitors [112-114]. These
compounds are competitive inhibitors of dGTP binding to
PolC [115], forming a three-hydrogen-bond base pair with
cytosine residues in the template DNA (Fig. 3A). Many
variations have been made on the original 6-AU scaffold,
producing several compounds that potently inhibit PolC
activity and bacterial growth in vitro [115-119]. Historically
however, 6-AUs have proven modest inhibitors of bacterial
growth in animal infection models due to poor solubility and
bioavailability [120]. Most compounds that have demonstrated activity in vivo have been tested using intraperitoneal
dosing, which largely circumvents the problems associated
with poor sample solubility. Recently, Svenstrup and colleagues addressed this issue by varying 3-substituents on the
6-AU scaffold with a view to improving aqueous solubility,

and in doing so have produced two compounds (Fig. 3B) that
show strong activity against S. aureus and Enterococcus
faecalis using intravenous dosing in a mouse infection model
[118]. It is hoped that this advance in understanding of the
structure-activity relationships of 6-AUs will facilitate the
development of clinically useful compounds.
Members of the second class of PolC inhibitors, the
BisQuinols, were discovered recently using high-throughput
fluorescence-based inhibition assays [121]. The methodology underlying these assays is described later in this section.
It was predicted that BisQuinols might base pair with cytosine residues in DNA templates and thus be competitive with
dGTP substrates, as observed for the 6-AUs. Biochemical
analysis revealed, however, that BisQuinols were uncompetitive with respect to nucleotide substrates, instead showing competitive behaviour against template DNA. The
mechanism of PolC inhibition by BisQuinols must therefore
be different to that of 6-AU compounds and appears to be
more analogous to that of non-nucleoside reverse transcripttase inhibitors used to treat HIV infections [121, 122].
Importantly, the initial series of BisQuinol compounds also
showed significant inhibition of the eukaryotic Pol  and
thus appears to show poor selectivity for bacterial DNA
polymerases [121]. Nevertheless, one representative compound (Fig. 3C) was found to be somewhat effective in
rescuing mice from a lethal intraperitoneal S. aureus
infection, thus demonstrating a degree of in vivo efficacy. A
better understanding of the structure-activity relationships
for this novel class of PolC inhibitors is now required to
assess their potential for development into functional
antibiotics.
A promising new strategy for the development of PolC
inhibitors is to covalently link 6-anilinouracil derivatives to
fluoroquinolones to create hybrid PolC-DNA gyrase inhibitors. These hybrid compounds maintain dual anti-PolC and
anti-DNA gyrase activity in vivo and have greater or equal
potency against whole bacterial cells than their isolated 6AU or fluoroquinolone parent compounds [116, 123, 124].
In fact when testing one representative hybrid (Fig. 3D),
Butler and colleagues observed that the fusion to fluroquinolone actually increased the anti-PolC activity of the 6-
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Fig. (3). DNA polymerase inhibitors. (A) Three-hydrogen-bond interaction between 6-anilinouracil compounds and a cytosine residue
within DNA [115]. Chemical structures of (B) new 6-anilinouracil derivatives with improved aqueous solubility [118], (C) a BisQuinol
inhibitor of PolC [121], (D) a hybrid PolC/DNA gyrase inhibitor [116], and (E) novel replisome inhibitors identified by high-throughput
screening [127].

AU moiety [116]. Even more promisingly, in cases where
each of the parent compounds was only weakly active in
isolation, i.e. for drug-resistant organisms, the hybrid compound was found to offer greater potency than an equimolar
mixture of its parents. The hybrid compound was thus
effective against a broader range of bacterial strains than
either parent, an attribute also observed for oxazolidinonequinolone hybrid protein synthesis/DNA gyrase inhibitors
[125, 126]. The use of hybrid inhibitors intuitively should

provide greater protection against the development of drug
resistance by target mutagenesis than traditional single-target
inhibitors – this would require co-mutation of two loci in the
bacterial population. This indeed appears to be the case for
Butler’s hybrid compound, for which resistance in S. aureus
was seen to develop far more slowly than resistance to either
parent compound in a simple pure culture system [116].
Several bacterial replisomes have now been reconstituted
and are functional in vitro [26-28, 30, 127]. For E. coli and
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B. subtilis, this includes all the machinery required for both
leading and lagging strand synthesis [26, 27]. For other
species, more minimal replisomes capable only of leading
strand synthesis have been assembled [28, 30]. Recently,
Dallmann and colleagues described a high-throughput assay
to screen for inhibitors of reconstituted replicase activity,
making use of an intercalating fluorescent dye to monitor
conversion of single-stranded DNA substrates into a doublestranded product [127]. This approach has a significant
advantage over assays that focus on isolated replication
components, in that inhibitors of any part of the replication
machinery can be identified through a common endpoint.
These workers also included specificity assays to test if
compounds bind to DNA, or inhibit viral and eukaryotic
DNA polymerases, RNA polymerase, an unrelated eukaryotic ATPase or an unrelated control enzyme, -galactosidase.
Using these assays, they screened a small library of 2000
compounds and identified seven (Fig. 3E) that act as specific
inhibitors of bacterial replisomes and kill bacterial cells by
inhibiting DNA replication. This high-throughput assay
approach thus provides an efficient means to generate lead
compounds for further drug development, and could be
applied equally well for screening natural product and
commercially available libraries of drug-like compounds.
Inhibitors of Primosome Functions
Outside of DNA gyrase and the replicative polymerases,
another replication subcomplex to be targeted for drug discovery has been the primosome, comprised of the DnaB/C
helicase and DnaG primase (see Table 1). These proteins
play critical roles in lagging strand synthesis and are essential for bacterial growth [40, 85, 128]. These proteins are
targets for some naturally occurring DNA replication
inhibitors. The dietary flavonoid myricetin (Fig. 4A), for
instance, has antimicrobial activity and has been shown to
potently inhibit the replicative helicase, but not primase
[129]. The bacterial alarmone compound (p)ppGpp on the
other hand, is now known to inhibit the activity of primase,
thereby halting DNA replication as part of the stringent
response [130, 131]. The existence of these natural, low
molecular weight inhibitors lends hope that the primosome
subcomplex might be a viable target for drug discovery.
The replicative helicase has two functional domains. The
N-terminal domain recruits primase to the replication fork,
while helicase activity stems from the C-terminal domain.
The helicase domain belongs to the RecA-type family of
ATPases [132], which includes the bacterial replication/
recombination/repair proteins RepA [133] and RecA [134],
the transcription termination factor Rho [135] as well as the
eukaryotic DNA repair proteins Rad51 and DMC1 [136]. On
the other hand, primase has a central RNA polymerase
domain that is not related to other RNA polymerases and has
a uniquely-shaped active site [137]. This domain is flanked
by an N-terminal zinc-binding domain, which binds to
specific trinucleotide initiation sequences on the template
DNA, and a C-terminal domain that binds to the helicase
[138]. Primase interacts with the helicase to enable primer
synthesis on the lagging strand in vivo [32]. This interaction
stimulates the activity of both proteins in vitro [139] and
varies in strength, ranging from a weak and transient
complex as observed for the E. coli proteins [140] to a highly
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stable complex as for the G. stearothermophilus proteins
[37].
In recent years high-throughput biochemical assays have
been developed to measure the activities of helicase and
primase, as well as the mutually stimulatory effects of their
interaction [141-143]. Application of these assays in drug
discovery has been limited, however, and has produced only
a few inhibitors [144-146]. The Förster resonance energy
transfer (FRET) assay for DnaB helicase activity developed
by Zhang and colleagues [141], for instance, has been used
by researchers at Targanta Therapeutics to screen a library of
230,000 commercially available compounds for inhibitors of
P. aeruginosa DnaB [147]. The Pseudomonas DnaB helicase
was used as it can be efficiently loaded onto substrate DNA
molecules in the absence of a helicase loader protein, in
contrast to the equivalent helicases from E. coli and B.
subtilis [61, 148]. Their screen revealed a triaminotriazine
compound that inhibited the helicase with IC50 = 5 μM (Fig.
4B). Despite showing potent inhibition of the P. aeruginosa
DnaB in vitro, neither the newly identified compound nor
analogs prepared to explore effects on cytotoxicity were
found to inhibit the growth of P. aeruginosa cells, despite
the fact that a permeability barrier-deficient strain was used
[147]. Some compounds were, however, moderately active
in inhibiting the growth of S. aureus, S. pneumoniae and a
hyper-susceptible strain of E. coli. Unfortunately, this series
of compounds exhibited a range of undesirable properties,
including cytotoxicity towards HeLa cells and loss of
antimicrobial activity in the presence of serum, that
ultimately deem them unsuitable as lead compounds for
antibiotic development. To date this represents the only
reported systematic attempt to identify specific inhibitors of
replicative helicase function.
DNA primase has attracted slightly more attention as a
drug target, although success has again been limited. To date
all searches for inhibitors have utilized the scintillation
proximity assay for primase activity developed by Zhang and
colleagues [141]. The assay is based on the ability of
primase to incorporate radioactive 3H-labeled NTP substrates
into an RNA product, which is then captured using a biotin
tag on the template DNA strand to which the RNA product
remains hybridized. Researchers at Schering Plough used
this assay to screen extracts of various plants for inhibitors of
E. coli primase [144], unearthing two novel phenolic
saccharides from Polygonum cusoidatum that produced IC50
values < 5 μM (Fig. 4C). Unfortunately, these compounds
appear to act by binding to the template DNA rather than to
primase itself and are therefore not appropriate lead
compounds [129, 144]. In another similar study conducted
by Schering Plough researchers, a novel bicyclic macrolide
compound, Sch 642305 (Fig. 4D), was isolated from the
fungus Penicillium verrucosum and found to inhibit E. coli
primase with an IC50 of 70 μM [146]. Promisingly, Sch
642305 also inhibited the growth of the E. coli strain HS294
(defective lipopolysaccharide layer and disrupted acrAB
efflux pump) with an MIC of 40 μg/mL. As yet no attempts
have been reported to establish the mode of Sch 642305
inhibition. Presumably this is due to difficulty in obtaining
sufficient material for biochemical analysis, although several
synthetic approaches for production of Sch 642305 have now
been described [149-151]. Before Sch 642305 can be
considered as a lead compound, further work is required to
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determine its mode of action, as well as its efficacy against
other bacterial strains in both in vitro cell growth and in vivo
animal infection models.
Making use of the high-resolution crystal structure of the
RNA polymerase domain of E. coli primase [137], Agarwal
and colleagues at Achillion Pharmaceuticals used virtual
screening to identify three potentially ‘druggable’ sites
within primase [145]. They selected 79 compounds predicted
to bind at these sites, and using the scintillation proximity
assay [152] identified four inhibitors with IC50 values of 7–
50 μM [145]. None of these compounds was active in
inhibiting the growth of E. coli cells, however. The initial
four compounds were used to deduce a three-dimensional
pharmacophore, which was then used to search a database of
commercially available compounds for other potential
inhibitors. From this search, a further 34 chemically diverse
compounds were selected for enzyme inhibition assays,
revealing eight additional compounds that inhibited primase
with IC50 values < 100 μM. Three of these also inhibited the
growth of E. coli, with MIC values of 4–64 μg/mL (Fig. 4E).
Analogs of these compounds were then studied with these
assays, allowing structure-activity relationships to be

deduced for each chemical series [145]. Further work is now
required to assess the efficacy of these compounds against
other bacterial strains for antibiotic development.
Inhibitors of the Initiation of DNA Replication
A relatively new approach towards the discovery of DNA
replication inhibitors is to target the initiation stage. In
(almost) all bacteria, the first step in replicating the
chromosome is the binding of multiple DnaA molecules at
the origin, which ultimately leads to separation of the two
template strands [153]. Since this step signifies commitment
to a complete round of replication, the amount and activity
of DnaA is tightly regulated within the cell. Insufficient
DnaA leads to under-initiation, while excess leads to overinitiation. Both disrupt cell growth. Currently, no
antibacterial agents target the initiation process.
Fossum and colleagues have recently developed a robust
cell-based assay to screen for inhibitors of DnaA activity
[154]. The assay utilises an E. coli strain containing a novel
dnaA allele that produces an over-active DnaA variant and
confers a cold-sensitive phenotype. This strain grows well at
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the permissive temperature (42˚C), but grows poorly at 30˚C
due to excessive initiation of DNA replication. Compounds
that inhibit DnaA activity reduce the initiation rate and thus
restore cell growth at 30˚C. This was demonstrated by
expressing moderate levels of the DnaA N-terminal domain,
a competitive inhibitor of full-length DnaA, within the cells.
While a small-scale screen of microbial extracts failed to
identify any inhibitors of DnaA activity, the simplicity of
this assay would easily facilitate larger screens and could
lead to the discovery of inhibitors in the future.
A second cell-based assay has been developed recently
with the aim of discovering inhibitors of replication initiation
in Vibrio spp. [155]. This group of bacteria includes the
causative agent of cholera, common sources of food
poisoning and pathogens of economically important marine
animals. Unlike most bacteria, Vibrio spp. contain two
chromosomes, only one of which is replicated in a DnaAdependent manner. Initiation of replication at the second
chromosome relies on the activity of a second protein, RctB,
that bears no sequence similarity to DnaA [156]. Yamaichi
and colleagues established a cell-based screen for identifying
inhibitors of V. cholerae RctB [155]. The assay uses an E.
coli strain that carries an RctB-dependent plasmid expressing
both RctB and a kanamycin-resistance marker. If RctB is
inhibited by a compound the cells cannot replicate the
plasmid and thus do not grow on kanamycin-containing
media. Using this strain, the group screened a library of
138,000 small molecules, identifying a potent inhibitor of
RctB, vibrepin, that inhibited the growth of all tested Vibrio
spp. but had no effect on the growth of wild-type E. coli
cells. If RctB inhibitors such as vibrepin can be developed
into functional antibiotics, they should only kill the
infectious Vibrio spp. whilst not affecting the natural gut
flora of a patient, offering a significant advantage over
current treatment options.
POTENTIAL
DISCOVERY

OPPORTUNITIES

FOR

DRUG

Structure-Aided Design
Despite the fact that three-dimensional structures are
known for most bacterial replication proteins, few attempts
to design novel inhibitors using structure-aided drug design
have been described. Structure-aided design involves in
silico screening of small molecule libraries, seeking to
identify compounds that dock into binding sites on the
surface of the target protein [157]. Docked ligands are then
expanded to maximize contacts with the protein, to optimise
the affinity of the small molecule for the binding site. A
major challenge is that X-ray crystal structures, the most
common source of structural data for proteins, provide only a
structural snapshot (i.e. a single conformation) that might not
reflect aspects of flexibility important for the in vivo activity
of the protein. Structure-aided design does have the advantage that structure-activity relationships can often be easily
deduced and important parameters can be rationalized on the
basis of the geometry of binding pockets. Historically however, compounds designed this way very often have problems with toxic side effects [158]. Nevertheless, a small
number of drugs produced using computer-aided design have
made it into clinical use [158, 159].
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The most common design strategy is to target enzyme
active sites within the protein structures [157]. The replication machinery includes DNA and RNA polymerase sites as
well as several ATPases. Given the ubiquity of ATP transactions in all living cells, these latter enzymes present a
significant challenge for rational design of inhibitors with
high specificity. Nonetheless, studies using bacteriophage
replicases have shown that it is possible to develop inhibitors
with specificity towards certain ATPase active sites over
others [160]. Given that many of the ATPases in the
bacterial replication machinery are related (Fig. 1B-C), it
might be possible to develop compounds that inhibit multiple
essential replication components, yet do not act on unrelated
ATPases. The mode of ATP binding has been deduced for
all of the replisome-associated AAA+ proteins and key residues comprising binding pockets have been identified [49,
57, 76, 161, 162]. Replicative and non-replicative AAA+
proteins could now be compared to assess similarities and
differences in binding sites that could be exploited to design
compounds that specifically inhibit bacterial DNA
replication.
The high-resolution crystal structure of G. kaustophilus
PolC in complex with template DNA and dGTP substrate
has provided the first detailed view of the active site of a
bacterial chromosomal replicase [163]. Residues comprising
the active site are highly conserved in the PolC subunits of
other firmicutes, including those of several pathogens. The
crystal structure of PolC will likely form an excellent model
for structure-aided drug design, particularly if further
structures can be solved for complexes with 6-anilinouraciltype inhibitors. Unfortunately, due to poor sequence conservation between PolC and DnaE1-type polymerases (e.g. the
Pol III  subunit) and the low resolution of structural
information for the ternary complex between DnaE1 and
DNA [164], it is difficult at the moment to model the DnaE1
active site. The specificity for 6-AUs towards PolC over
DnaE1-type polymerases suggests that there are significant
differences in architecture of active sites between the two
types. Higher-resolution data are required for DnaE1-DNAsubstrate complexes if this form of polymerase is to be used
in structure-aided design.
The replisome is a highly dynamic complex in which
many proteins are tethered to each other by way of flexible
linkers. Almost all of the extant structural data has involved
truncation of proteins to individual domains or removal of
flexible portions. Identifying constructs suitable for structure
determination has proven one of the key challenges in the
study of replication proteins. Now that crystallizable constructs are available, many are prime candidates for structurebased fragment screening approaches [165]. This strategy
involves determining many (often several hundred) highresolution structures of the protein of interest, after exposing
crystals of it to mixtures of drug-like fragments. Fragments
found to bind at adjacent sites on the protein surface are then
linked, producing a tighter-binding compound that acts as a
lead for drug development. Fragment-based screening uses
smaller compound libraries compared to other highthroughput screening approaches and has greater hit rates
against difficult targets [165]. It is anticipated that if applied
to replication proteins, fragment screening could yield novel
inhibitors of enzymatic activities and protein-protein interactions that are crucial for replication, and thus provide a
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starting point for the development of novel antibiotics that
target the DNA replication machinery.
Protein-Protein Interaction Hubs
The portions of replication proteins that form proteinprotein contacts are generally poorly conserved among
bacterial genera. There are, however, two protein-protein
interaction systems in bacterial replication that are extremely
well conserved – those based around the -sliding clamp and
SSB [21]. The -sliding clamp is known to bind (at least) to
DNA polymerases I, II, III, IV and V, DNA ligase, Hda,
MutS and MutL in E. coli, acting to recruit these proteins to
their sites of action on double-stranded DNA during
replication and repair processes [21, 45]. As far as is known,
each of these proteins binds to the same hydrophobic groove
on the -sliding clamp by way of a pentameric or hexameric
peptide motif, often located at or close to the N- or Cterminus [45]. The hydrophobic groove on the -sliding
clamp and its binding motifs in other proteins are strongly
conserved across bacterial species [21]. An analogous
mechanism is also shared by the PCNA sliding clamp of
archaea and eukaryotes, although the consensus sequence
recognised by PCNA is different from that of the bacterial binding motifs. The strong conservation of this protein
binding mechanism across bacteria, together with the
essentiality of many of the interactions formed at this single
site, makes the protein-binding groove of the -sliding clamp
an attractive target for rational antibiotic design.
The O’Donnell group has recently developed a highthroughput fluorescence polarization anisotropy assay for
identifying inhibitors of -clamp-DNA polymerase interactions [166]. The assay is based on the displacement of a
fluorescent TAMN-labeled peptide, derived from the E. coli
Pol III  subunit, from its binding site on the -clamp. From
a library of >30,000 small molecules, 91 inhibitors were
identified. These were then screened in a DNA replication
assay, revealing 19 compounds that specifically inhibited the
-dependent activity of Pol III HE. A subset of these compounds was also active in displacing a PolC-derived peptide
from S. pyogenes , consistent with the high level of conservation of protein-binding-site residues in subunits from
diverse bacteria [21]. One compound, RU7 (Fig. 5A), was
further capable of differential inhibition of binding of
various polymerases to , inhibiting the -dependent activities of Pol III and Pol II, but not Pol IV [166]. Importantly,
RU7 was found not to inhibit PCNA-dependent DNA synthesis by a model eukaryotic polymerase, yeast Pol . The
O’Donnell compounds seem to be useful leads that could
eventually be developed into a new class of bacterial DNA
replication inhibitors.
SSB also interacts with many DNA replication and repair
proteins by way of a conserved peptide motif, recruiting
them to their sites of action on single-stranded DNA [21,
46]. These interactions are mediated by the final 6–9
residues at the C-terminus of SSB [79], which in E. coli has
the sequence -MDFDDDIPF. These residues are highly
conserved across a wide range of bacterial species, indicating
that this system is probably used universally by bacteria. A
crystal structure of the terminal SSB peptide in complex with
exonuclease I shows the final two residues of SSB bind
within a hydrophobic pocket on the exonuclease I surface
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[167]. It is anticipated that its binding to other proteins
occurs in a similar fashion. By employing a fluorescence
polarization anisotropy assay similar to that developed for
monitoring -clamp interactions [166], Keck and colleagues
screened a library of >50,000 small molecules, identifying
four (Fig. 5B) that disrupt the interaction between the SSB
C-terminus and exonuclease I [168]. Of these, two contained
groups analogous to the Phe residue at the C-terminus of
SSB. Interestingly, these same two compounds inhibited
SSB interactions with RecQ and PriA, each structurally
unrelated to exonuclease I, demonstrating at least some
similarity in the arrangement of SSB binding sites in these
proteins. Given that the SSB protein interaction system is
conserved in bacteria, but not present in eukaryotes, it may
be possible to develop these compounds into selective
inhibitors of bacterial DNA replication.
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Fig. (5). Chemical structures of protein-protein interaction
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The -clamp and SSB interaction hubs are promising
novel drug targets. If inhibitors of these interactions can be
designed, they should be capable of simultaneously disrupting several functions critical to the survival of a bacterial
cell. Such inhibitors should also have broad-spectrum
activity as these modules are highly conserved. Finally, and
perhaps most crucially, the fact that numerous proteins
interact at a single site on each of these hubs should help to
preclude development of resistance to such inhibitors –
development of resistance by target modification would
require simultaneous mutation of many different essential
sites. The accumulation of point mutations that decrease the
affinity of inhibitory compounds for their target is a common
route to antibiotic resistance. In the case of protein-protein
interaction sites, any mutation occurring on one interacting
partner needs compensatory mutation(s) on another to
maintain the integrity of the (essential) interaction site. For
this to occur in the -clamp and SSB protein-binding sites, it
would necessitate the unlikely acquisition of simultaneous
compensatory mutations in the binding sites of many or all
of the numerous proteins that bind at these sites.
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